Index

Note: Page numbers of article titles are in **boldface** type.

**A**

Abstinence
  - in alcoholic hepatitis management, 723
  - in alcoholic liver disease management, 765–767

Abuse
  - alcohol. See Alcohol abuse

Acetaldehyde metabolism, 680–681

*N*-Acetylcysteine (NAC)
  - for alcoholic hepatitis, 727

Acute alcoholic hepatitis
  - liver transplantation for, 857–859

Adaptive immune system, 690–692
  - interleukins in, 691–692

S-Adenosylmethionine (SAMe)
  - in alcoholic liver disease management, 770

ADH reaction. See Alcohol dehydrogenase (ADH) reaction

Age
  - as factor in alcohol consumption, 662
  - as factor in alcohol elimination rate, 671

Age-bilirubin-INR creatinine score
  - in alcoholic hepatitis diagnosis, 722

Alcohol
  - as carcinogen, 845–846
    - data for, 840–841
  - catalase-dependent oxidation of, 676–677
  - chronic liver diseases effects of, **827–837**. See also Chronic liver diseases, alcohol effects on
  - diabetes related to, 843–844
  - dietary carcinogens and, 845
  - distribution in body, 668–669
  - harmful effects of, 660
  - HBV and, 842
  - HCC and, **839–850**
  - HCV and, 841–842
  - iron overload disorders related to, 844
  - liver cancer and, **839–850**. See also Liver cancer, alcohol and metabolic syndrome and, 843–844
  - obesity and, 843–844
  - smoking and, 842–843
  - in stomach
    - first-pass metabolism of, 669–670
Alcohol (continued)
  zonal metabolism of
    in hepatic acinus, 679–680
Alcohol absorption
  factors affecting, 669
Alcohol abuse, 737–762
  defined, 737–738
  described, 737–738
  diagnosis of, 739–741
  management of, 737–762
    behavioral therapies in, 750
    CAM, 754–755
    case example, 746–747
    determination of level of, 742–746
    detoxification in, 747–749
    motivational interviewing in, 749–750
    pharmacologic, 751–754
    stages of change in, 749–750
    support groups in, 755–756
    types of, 747–756
  prevalence of, 738–739
Alcohol consumption
  age and, 662
Alcohol dehydrogenase (ADH) reaction
  NADH generated by
    reoxidation of, 675–676
Alcohol dependency
  treatment of
    pharmaceutical, 766–767
    psychological, 766
Alcohol elimination
  rate of
    factors modifying, 671–672
    in vivo
      kinetics of, 671
Alcohol metabolism, 667–685
  catalase-dependent oxidation of alcohol in, 676–677
  conjugation reactions in, 680
  described, 687–688, 741–742
  general principles of, 670–671
  pathways of, 676–680
  reoxidation of NADH generated by ADH reaction in, 675–676
  scheme for, 672–675
  in stomach
    first-pass metabolism, 669–670
    substrate shuttles in, 676
    zonal
      in hepatic acinus, 679–680
Alcohol-related dementia
  in liver transplant candidates with alcoholic liver disease, 869–870
Alcohol-related liver injury
gender and, 662
Alcohol–drug interactions, 678–679
Alcoholic beverages
  consumption of
    history of, 659–660
Alcoholic cirrhosis. See also Alcoholic liver disease
  liver transplantation for, 865–875. See also Liver transplantation, for alcoholic liver disease
  management of
    dietary supplements used as antioxidants in, 819
    enteral supplementation in, 814
    parenteral supplementation in, 815
  surgical risks in
    assessment of, 771
Alcoholic hepatitis, 717–736
  acute
    liver transplantation for, 857–859
  described, 718
  diagnosis of, 718–722
    age-bilirubin-INR creatinine score in, 722
    Child-Turcotte-Pugh score in, 722
    GAHS in, 721–722
    histologic findings in, 720–721
    Lille model in, 722
    liver biopsy in, 719–720
    Maddrey’s discriminant function in, 721
    MELD score in, 721
    severity assessment in, 721–722
  prevalence of, 718
  risk factors for, 718
  signs and symptoms of, 718
  treatment of, 723–730
    abstinence in, 723
    antioxidants in, 727
    colchicine in, 728
    corticosteroids in, 724–726
    dietary supplements used as antioxidants in, 819
    enteral supplementation in, 814
    future targets in, 729–730
    hepatic regeneration therapy in, 728
    liver transplantation in, 729–730
    metadoxine in, 727
    NAC in, 727
    nonpharmacologic, 723
    nutritional therapy in, 723
    parenteral supplementation in, 814–815
    PCU in, 728
    pentoxifylline in, 726–727
    pharmacologic, 724–728
    polyunsaturated lecithins in, 728
    TNF-α in, 727
Alcoholic liver disease, 659–666
  antibiotic dosing in patients with, 796–799
  bone disease effects of, 773–774
  described, 763–764
  diagnosis of
    detection in, 764–765
  epidemiology of, 660–662
  ethnicity and, 662
  histologic findings in, 699–716. See also Histologic findings, in alcoholic liver disease
  immunology in, 687–698. See also Immunology, in alcoholic liver disease
  infections in, 783–803. See also Infection(s), in alcoholic liver disease
  liver transplantation for, 851–863. See also Liver transplantation, for alcoholic liver
disease
  management of
    long-term, 763–781
      abstinence in, 765–767
      anabolic-androgenic steroids in, 771
      antioxidants in, 769
      colchicine in, 769–770
      complications of
        prevention of, 772–773
        detection in, 764–765
        glutathione prodrugs in, 770
        liver transplantation in, 774
        nutritional therapy in, 767–768
      overview of, 764–767
      pentoxifylline in, 769
      probiotics in, 770–771
      proposed liver-specific therapy in, 767–771
      PTU in, 769
      SAMe in, 770
      silymarin/milk thistle in, 770
  natural history of, 662–664
  nutrition in, 805–826. See also Nutrition, in alcoholic liver disease
  protein calorie malnutrition in, 805–806

Alcoholism
  as factor in alcohol elimination rate, 672

Amino acids
  branched-chain
    in nutrition management in alcoholic liver disease, 815–818

Anabolic-androgenic steroids
  in alcoholic liver disease management, 771

Anabolic steroids
  for alcoholic hepatitis, 728

Anthropometry
  bedside
    in nutrition assessment in alcoholic liver disease, 810–811

Anti-inflammatory factors
  in alcoholic liver disease, 693–694

Antibiotics
  in alcoholic liver disease patients, 796–799
Antioxidants
  in alcoholic hepatitis, 727
  in alcoholic liver disease, 769
dietary supplements used as
  in nutrition management in alcoholic liver disease, 818–819
Apoptosis
  in alcoholic liver disease
  necrosis and, 707
Ascites
  alcoholic cirrhosis and
  prevention of, 772
Autoimmune liver diseases
  alcohol effects on, 832–833

B
Balooning degeneration
  in alcoholic liver disease
    oncotic necrosis due to, 702–704
Bedside anthropometry
  in nutrition assessment in alcoholic liver disease, 810–811
Behavioral therapies
  in alcohol abuse management, 750
Biologic rhythms
  as factor in alcohol elimination rate, 672
Bone disease
  alcoholic liver disease effects on, 773–774
Branched-chain amino acids
  in nutrition management in alcoholic liver disease, 815–818

C
CAM. See Complementary and alternative medicine (CAM)
Cancer
  after liver transplantation for alcoholic liver disease, 870–871
    liver
      alcohol and, 839–850. See also Liver cancer, alcohol and
CAP. See Community-acquired pneumonia (CAP)
Cardiac disease
  after liver transplantation for alcoholic liver disease, 866–867
Cardiovascular system
  infections of
    in alcoholic liver disease, 787–788
Child-Turcotte-Pugh score
  in alcoholic hepatitis diagnosis, 722
Chronic liver diseases
  alcohol effects on, 827–838. See also specific diseases
    autoimmune liver diseases, 832–833
    chronic HBV, 831–832
Chronic (continued)
  chronic HCV, 829–831
  hemochromatosis, 832
Cirrhosis
  alcoholic. See Alcoholic cirrhosis
  fibrosis’ progression to, 708–712
  natural history of, 663–664
Coffee
  in nutrition management in alcoholic liver disease, 819
Coinfection viral hepatitis
  in alcoholic liver disease, 791
Colchicine
  in alcoholic hepatitis, 728
  in alcoholic liver disease, 769–770
Community-acquired pneumonia (CAP)
  in alcoholic liver disease, 785
Complement pathway
  in alcoholic liver disease, 692–693
Complementary and alternative medicine (CAM)
  in alcohol abuse management, 754–755
Conjugation reactions
  alcohol metabolism by, 680
Corticosteroids
  in alcoholic hepatitis, 724–726
Cytokeratins
  in alcoholic liver disease, 704–705

D
Decompensated liver disease
  prevention of, 772–773
Deconditioning
  after liver transplantation for alcoholic liver disease, 867–868
Dementia
  alcohol-related
    in liver transplant candidates with alcoholic liver disease, 869–870
Detoxification
  in alcohol abuse management, 747–749
DFI. See Discriminant function index (DFI)
Diabetes
  alcohol and, 843–844
Dietary carcinogens
  alcohol and, 845
Dietary supplements
  used as antioxidants
    in nutrition management in alcoholic liver disease, 818–819
Discriminant function index (DFI)
  in alcoholic hepatitis diagnosis, 721
Drug(s)
  as factor in alcohol elimination rate, 672
Drug–alcohol interactions, 678–679
E
Encephalopathy(ies)
  hepatic
    alcoholic cirrhosis and prevention of, 772–773
Endocarditis
  in alcoholic liver disease, 787–788
Endotoxin
  in innate immune system, 688–689
Enteral supplementation
  in nutrition management in alcoholic liver disease, 813–814
Enteric infections
  in alcoholic liver disease, 791–792
Ethanol
  metabolism of, 741–742
  microsomal oxidation of, 677–678
  pharmacology of, 741–742
Ethnicity
  alcohol-related liver disease related to, 662
  as factor in alcohol elimination rate, 671–672
Exercise
  as factor in alcohol elimination rate, 672

F
Fatty acyl synthases
  alcohol metabolism by, 680
Fibrosis
  in alcoholic liver disease
    progression to cirrhosis, 708–712
    innate immune system and, 690
Food
  as factor in alcohol elimination rate, 672

G
GAHS (Glasgow Alcoholic Hepatitis Score)
  in alcoholic hepatitis diagnosis, 721–722
Gastroesophageal varices
  alcoholic cirrhosis and prevention of, 772
Gastrointestinal system
  infections of
    in alcoholic liver disease, 788–792
      coinfection viral hepatitis, 791
      enteric infections, 791–792
      infected pancreatic pseudocyst, 788–789
      spontaneous bacterial peritonitis, 789–791
Gender
  as factor in alcohol elimination rate, 671
  as factor in alcohol-related liver injury, 662
Glutathione prodrugs
  in alcoholic liver disease management, 770

H

HBV. See Hepatitis B virus (HBV)
HCC. See Hepatocellular carcinoma (HCC)
HCV. See Hepatitis C virus (HCV)
Hemochromatosis
  alcohol effects on, 832
Hepatic acinus
  zonal metabolism of alcohol in, 679–680
Hepatic encephalopathy
  alcoholic cirrhosis and
    prevention of, 772–773
Hepatic redox state, 675
Hepatic regeneration therapy
  for alcoholic hepatitis, 728
Hepatic steatosis
  lipid accumulation and
    in alcoholic liver disease, 700–702
    natural history of, 662–663
Hepatitis
  alcoholic, 717–736. See Alcoholic hepatitis
    viral
      coinfection
        in alcoholic liver disease, 791
Hepatitis B virus (HBV)
  alcohol and, 842
    chronic
      alcohol effects on, 831–832
Hepatitis C virus (HCV)
  alcohol and, 841–842
    chronic
      alcohol effects on, 829–831
Hepatocellular carcinoma (HCC)
  alcohol and, 839–850
    described, 839–840
    epidemiology of, 840–845
    alcoholic cirrhosis and
      prevention of, 773
Hepatorenal syndrome
  alcoholic cirrhosis and
    prevention of, 773
Histologic findings
  in alcoholic hepatitis diagnosis, 720–721
  in alcoholic liver disease, 699–716
    apoptosis and necrosis, 707
    balloononing degeneration
      oncotic necrosis due to, 702–704
    described, 699–700
differential diagnosis of, 712–713
fibrosis, 708–712
inflammation, 705–707
lipid accumulation
  hepatic steatosis due to, 700–702
Mallory bodies, 704–705
regeneration, 707–708

I
Immune system
  adaptive, 690–692
  innate, 688–690
Immunology
  in alcoholic liver disease, 687–698
    adaptive immune system, 690–692
    anti-inflammatory factors, 693–694
    complement pathway, 692–693
    innate immune system, 688–690
Kupffer cells in, 689–690
Infection(s)
  in alcoholic liver disease, 783–803. See also specific infections
    cardiovascular system–related, 787–788
    clinical syndromes by organ system, 784–796
    described, 783–784
    gastrointestinal system–related, 788–792
    nervous system–related, 792
    respiratory tract–related, 784–786
    systemic infections, 793–796
Inflammation
  in alcoholic liver disease, 705–707
Innate immune system, 688–690
  endotoxin in, 688–689
Kupffer cells in, 689–690
Interleukin(s)
  in adaptive immune system, 691–692
Interviewing
  motivational
    in alcohol abuse management, 749–750
Iron overload disorders
  alcohol and, 844

K
Kupffer cells
  in innate immune system, 689–690

L
Lecithins
  polyunsaturated
    for alcoholic hepatitis, 728
Lille model
  in alcoholic hepatitis diagnosis, 722
Lipid(s)
  in alcoholic liver disease
    hepatic steatosis due to, 700–702
Liver biopsy
  in alcoholic hepatitis diagnosis, 719–720
Liver cancer
  alcohol and, 839–850
    epidemiology of, 840–845
    pathogenesis of, 845–846
Liver disease(s)
  autoimmune
    alcohol effects on, 832–833
  chronic
    alcohol effects on, 827–838. See also specific diseases and Chronic liver diseases,
    alcohol effects on
    decompensated
      prevention of, 772–773
  nonalcoholic fatty liver, 827–829
Liver transplantation
  for alcoholic hepatitis, 729–730
  for alcoholic liver disease, 774, 851–863
    acute alcoholic hepatitis, 857–859
    alcohol use after, 871–873
    alcohol use before, 871–873
  complications of, 865–875
    cancer, 870–871
    cardiac disease, 866–867
    deconditioning, 867–868
    malnutrition, 867
    neurologic issues, 868–870
    osteoporosis, 870
    described, 851–852
    indications for, 865
    patient evaluation for, 852–854
      medical evaluation, 853
      psychosocial evaluation, 853–854
    patient referral for, 852
    relapse following
      defining of, 856
      monitoring for, 856–857
      6-month rule for, 854–856
LPS/TLR-4 signaling pathway
  in innate immune system, 689–690
Lung abscess/empyema
  in alcoholic liver disease, 785–786

M

Mallory bodies
  in alcoholic liver disease, 704–705
Malnutrition
after liver transplantation for alcoholic liver disease, 867
mechanisms of, 806–809
decreased absorption, 807
decreased oral intake, 806–807
decreased synthesis, secretion, and stores, 807
hypermetabolic state, 808
micronutrient deficiencies, 808–809
vitamin deficiencies, 808–809
protein calorie
in alcoholic liver disease, 805–806
MELD (Model for End-Stage Liver Disease) score
in alcoholic hepatitis diagnosis, 721
Metabolic syndrome
alcohol related to, 843–844
Metadoxine
for alcoholic hepatitis, 727
Micronutrient deficiencies
manutrition due to, 808–809
Motivational interviewing
in alcohol abuse management, 749–750

N
NAC. See N-Acetylcysteine (NAC)
NAFLD. See Nonalcoholic fatty liver disease (NAFLD)
Nervous system
infections of
in alcoholic liver disease, 792
Neurologic disorders
after liver transplantation for alcoholic liver disease, 868–870
alcohol-related dementia, 869–870
Nicotinamide adenine dinucleotide
reduced
reoxidation of
ADH reaction related to, 675–676
Nonalcoholic fatty liver disease (NAFLD), 827–829
Nutrition
in alcoholic hepatitis, 723
in alcoholic liver disease, 767–768, 805–826
assessment of, 809–812
bedside anthropometry in, 810–811
clinical assessment, 809–810
laboratory evaluation in, 811
in routine practice, 811–812
management of, 812–819
branched-chain amino acids in, 815–818
coffee drinking in, 819
described, 812–813
dietary supplements used as antioxidants in, 818–819
Nutrition (continued)
    enteral supplementation in, 813–814
    oxandrolone in, 819
    parenteral nutrition in, 814–815

O
Obesity
    alcohol and, 843–844
Oncotic necrosis
    in alcoholic liver disease
        ballooning degeneration and, 702–704
Osteoporosis
    after liver transplantation for alcoholic liver disease, 870
Oxandrolone
    in nutrition management in alcoholic liver disease, 819

P
Pancreatic pseudocyst
    infected
        in alcoholic liver disease, 788–789
Parenteral nutrition
    in nutrition management in alcoholic liver disease,
        814–815
PCU. See Propylthiouracil (PCU)
Pentoxifylline
    for alcoholic hepatitis, 726–727
    in alcoholic liver disease management, 769
Peritonitis
    spontaneous bacterial
        alcoholic cirrhosis and
            prevention of, 772
    in alcoholic liver disease, 789–791
Pneumonia
    community-acquired
        in alcoholic liver disease, 785
Polyunsaturated lecithins
    for alcoholic hepatitis, 728
Probiotics
    in alcoholic liver disease management, 770–771
Propylthiouracil (PCU)
    in alcoholic hepatitis management, 728
    in alcoholic liver disease management, 769
Protein calorie malnutrition
    in alcoholic liver disease, 805–806
Pseudocyst(s)
    pancreatic
        infected
            in alcoholic liver disease, 788–789
R

Reactive oxygen species
  in innate immune system, 690

Respiratory system
  infections of
    in alcoholic liver disease, 784–786
      CAP, 785
      lung abscess/empyema, 785–786
      TB, 786

Rickettsioses
  in alcoholic liver disease, 795–796

S

SAMe. See S-Adenosylmethionine (SAMe)

Silymarin/milk thistle
  in alcoholic liver disease management, 770

Smoking
  alcohol and, 842–843

Spontaneous bacterial peritonitis
  alcoholic cirrhosis and
    prevention of, 772
  in alcoholic liver disease, 789–791

Stages of change
  in alcohol abuse management, 749–750

Steatohepatitis
  inflammation and, 705–707
  natural history of, 663

Steroid(s)
  anabolic
    for alcoholic hepatitis, 728
  anabolic-androgenic
    in alcoholic liver disease management, 771

Substrate shuttles
  in alcohol metabolism, 676

Support groups
  in alcohol abuse management, 755–756

Systemic infections
  in alcoholic liver disease, 793–796
    Capnocytophaga spp., 794–795
    Vibrio vulnificus, 793–794

T

TB. See Tuberculosis (TB)

TNF-α. See Tumor necrosis factor-α (TNF-α)

Transplantation
  liver. See Liver transplantation

Tuberculosis (TB)
  in alcoholic liver disease, 786
Tumor necrosis factor-α (TNF-α)
   for alcoholic hepatitis, 727

V
Varice(s)
   gastroesophageal
   alcoholic cirrhosis and
   prevention of, 772
Vibrio vulnificus
   in alcoholic liver disease, 793–794
Viral hepatitis
   coinfection
   in alcoholic liver disease, 791
Vitamin deficiencies
   malnutrition due to, 808–809